https://www.ncbi.nlm.nih.gov/pubmed/?term=H5N1+candidate+vaccine
Otan esiin niitä jotka ovat "2017" aikaisia artikkeleita ja nyt hakutulosmäärä on 10 kpl, jtoen voin otaa sitaatin tähän.
Search results
Items: 10
1.
Pitisuttithum
P, Boonnak K, Chamnanchanunt S, Puthavathana P, Luvira V, Lerdsamran H,
Kaewkungwal J, Lawpoolsri S, Thanachartwet V, Silachamroon U, Masamae
W, Schuetz A, Wirachwong P, Thirapakpoomanunt S, Rudenko L, Sparrow E,
Friede M, Kieny MP.
Lancet Infect Dis. 2017 May 19. pii: S1473-3099(17)30240-2. doi: 10.1016/S1473-3099(17)30240-2. [Epub ahead of print]
Abstract
The emergence of highly pathogenic avian influenza H5N1 viruses has raised concerns about their pandemic potential. Vaccination is the most effective way of preventing influenza. In this study, we investigated the safety and immunogenicity of an avian H5N2 live attenuated influenza vaccine (LAIV H5N2) in healthy Thai adults and its priming immune responses with an H5N1 inactivated vaccine boost......" Importantly, higher cross-reactive haemagglutination-inhibition antibody titres against H5N1 (clades 1, 2.1.3.2, and 2.3.4) were detected in the LAIV H5N2 experienced group than the naive group (p<0 p="">Free Article
2.
Boonnak K, Matsuoka Y, Wang W, Suguitan AL Jr, Chen Z, Paskel M, Baz M, Moore I, Jin H, Subbarao K.
J Virol. 2017 May 10. pii: JVI.00547-17. doi: 10.1128/JVI.00547-17. [Epub ahead of print]
--" The second approach was to select a low pathogenicity avian influenza H5
virus that elicited antibodies that cross-reacted with a broad range of
H5 viruses," ---
3.
Zou Z, Huang K, Wei Y, Chen H, Liu Z, Jin M.
Sci Rep. 2017 May 3;7(1):1478. doi: 10.1038/s41598-017-01554-1.
(trivalenttista rokotetta hanhille) ---" Duck enteritis virus (DEV), duck tembusu virus (DTMUV), and highly pathogenic avian influenza virus (HPAIV) H5N1 are the most important viral pathogens in ducks, as they cause significant economic losses in the duck industry"
4.
Wang Y, Wu J, Xue C, Wu Z, Lin Y, Wei Y, Wei X, Qin J, Zhang Y, Wen Z, Chen L, Liu GD, Cao Y.
Antiviral Res. 2017 Jul;143:97-105. doi: 10.1016/j.antiviral.2017.03.029. Epub 2017 Apr 10.
---"In summary, this study presents a better vaccine candidate
(H7N9-53TM) against H7N9 pandemics. Furthermore, our HA-based
structural design approach would be conceivably applicable to other
subtype influenza viruses, especially the viruses from emerging pandemic
and epidemic influenza viruses such as H5N1 and H1N1".
5.
Tao W, Hurst BL, Shakya AK, Uddin MJ, Ingrole RS, Hernandez-Sanabria M, Arya RP, Bimler L, Paust S, Tarbet EB, Gill HS.
Antiviral Res. 2017 May;141:62-72. doi: 10.1016/j.antiviral.2017.01.021. Epub 2017 Feb 2.
---"The extracellular domain of influenza A ion channel membrane matrix protein 2 (M2e) is considered to be a potential candidate to develop a universal influenza A vaccine. However poor immunogenicity of M2e presents a significant roadblock."
6.
Ingle NB, Virkar RG, Arankalle VA.
Front Immunol. 2017 Jan 9;7:674. doi: 10.3389/fimmu.2016.00674. eCollection 2016.
---"The protection conferred by Mw-HNM correlated with induction of IFN-γ, CD8+ T cytotoxic cells, and CD4+ T helper cells. Mw-adjuvanted HA + NP + M2e combination represents a promising vaccine candidate deserving further evaluation.Free PMC Article---"
7.
Lee I, Il Kim J, Park S, Bae JY, Yoo K, Yun SH, Lee JY, Kim K, Kang C, Park MS.
Sci Rep. 2017 Jan 13;7:40675. doi: 10.1038/srep40675.
--"Taken all together, our results suggest the PA E31K mutation as a
single, substantial growth determinant of avian influenza CVVs and for
the establishment of a high-yield avian influenza vaccine backbone.Free PMC Article"
8.
Volz A, Sutter G.
Adv Virus Res. 2017;97:187-243. doi: 10.1016/bs.aivir.2016.07.001. Epub 2016 Aug 1. Review.
Safety tested Modified Vaccinia virus Ankara (MVA) is licensed as third-generation vaccine against smallpox and serves as a potent vector system for development of new candidate vaccines
against infectious diseases and cancer. Historically, MVA was developed
by serial tissue culture passage in primary chicken cells of vaccinia
virus strain Ankara, and clinically used to avoid the undesirable side
effects of conventional smallpox vaccination. Adapted to growth in avian
cells MVA lost the ability to replicate in mammalian hosts and lacks
many of the genes orthopoxviruses use to conquer their host (cell)
environment. As a biologically well-characterized mutant virus, MVA
facilitates fundamental research to elucidate the functions of poxvirus
host-interaction factors. As extremely safe viral vectors MVA vaccines
have been found immunogenic and protective in various preclinical
infection models. Multiple recombinant MVA currently undergo clinical
testing for vaccination against human immunodeficiency viruses,
Mycobacterium tuberculosis or Plasmodium falciparum. The versatility of
the MVA vector vaccine platform is readily demonstrated by the swift development of experimental vaccines
for immunization against emerging infections such as the Middle East
Respiratory Syndrome. Recent advances include promising results from the
clinical testing of recombinant MVA-producing antigens of highly
pathogenic avian influenza virus H5N1
or Ebola virus. This review summarizes our current knowledge about MVA
as a unique strain of vaccinia virus, and discusses the prospects of
exploiting this virus as research tool in poxvirus biology or as safe
viral vector vaccine to challenge existing and future bottlenecks in vaccinology.
9.
Nguyen
DT, Jang Y, Nguyen TD, Jones J, Shepard SS, Yang H, Gerloff N, Fabrizio
T, Nguyen LV, Inui K, Yang G, Creanga A, Wang L, Mai DT, Thor S,
Stevens J, To TL, Wentworth DE, Nguyen T, Pham DV, Bryant JE, Davis CT.
J Virol. 2017 Feb 14;91(5). pii: e01708-16. doi: 10.1128/JVI.01708-16. Print 2017 Mar 1.
IMPORTANCE Highly pathogenic avian influenza (HPAI) A(H5) viruses
have circulated continuously in Vietnam since 2003, resulting in
hundreds of poultry outbreaks and sporadic human infections. Despite a
significant reduction in the number of human infections in recent years,
poultry outbreaks continue to occur and the virus continues to
diversify. Vaccination of poultry has been used as a means to control
the spread and impact of the virus, but due to the diversity and
changing distribution of antigenically distinct viruses, the utility of vaccines
in the face of mismatched circulating strains remains questionable.
This study assessed the putative amino acid changes in viruses leading
to antigenic variability, underscoring the complexity of vaccine
selection for both veterinary and public health purposes. Given the
overlapping geographic distributions of multiple, antigenically distinct
clades of HPAI A(H5) viruses in Vietnam, the vaccine efficacy of bivalent poultry vaccine formulations should be tested in the future.
10.
Pua TL, Chan XY, Loh HS, Omar AR, Yusibov V, Musiychuk K, Hall AC, Coffin MV, Shoji Y, Chichester JA, Bi H, Streatfield SJ.
Hum Vaccin Immunother. 2017 Feb;13(2):306-313. doi: 10.1080/21645515.2017.1264783. Epub 2016 Dec 8.
Highly pathogenic avian influenza (HPAI) H5N1
is an ongoing global health concern due to its severe sporadic
outbreaks in Asia, Africa and Europe, which poses a potential pandemic
threat. The development of safe and cost-effective vaccine
candidates for HPAI is considered the best strategy for managing the
disease and addressing the pandemic preparedness. The most potential vaccine candidate
is the antigenic determinant of influenza A virus, hemagglutinin (HA).
The present research was aimed at developing optimized expression in
Nicotiana benthamiana and protein purification process for HA from the
Malaysian isolate of H5N1 as a vaccine antigen for HPAI H5N1.
Expression of HA from the Malaysian isolate of HPAI in N. benthamiana
was confirmed, and more soluble protein was expressed as truncated HA,
the HA1 domain over the entire ectodomain of HA. Two different
purification processes were evaluated for efficiency in terms of purity
and yield. Due to the reduced yield, protein degradation and length of
the 3-column purification process, the 2-column method was chosen for
target purification. Purified HA1 was found immunogenic in mice inducing
H5 HA-specific IgG and a hemagglutination inhibition antibody. This
paper offers an alternative production system of a vaccine candidate against a locally circulating HPAI, which has a regional significance.
Inga kommentarer:
Skicka en kommentar